Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
August 11 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that C. Russell Trenary III,
President and Chief Executive Officer of Outlook Therapeutics, will
participate in the H.C. Wainwright Ophthalmology Virtual Conference
being held Tuesday, August 17, 2021 from 9:00 – 10:00 a.m. ET .
As part of the event, Mr. Trenary will
participate in the panel, hosted by Matthew Caufield, Equity
Research Analyst at H.C. Wainwright, The Greatest Unmet Needs
Facing Ophthalmology Today. To register for the event, please visit
the conference website here.
Outlook Therapeutics recently announced positive
clinical and highly statistically significant top-line results from
its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating
ONS-5010 / LYTENAVA™ (bevacizumab) for treatment of neovascular
age-related macular degeneration (wet AMD). Because no currently
approved ophthalmic formulations of bevacizumab are available,
clinicians wishing to treat retinal patients with bevacizumab have
had to use unapproved repackaged IV bevacizumab provided by
compounding pharmacists, products that have known risks of
contamination and inconsistent potency and availability.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010 / LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
file ONS-5010 ophthalmic bevacizumab with the U.S. FDA as a new BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical
facts are “forward-looking statements,” including those relating to
future events. In some cases, you can identify forward-looking
statements by terminology such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “anticipate,” “project,” “believe,” “estimate,”
“predict,” “potential,” “intend” or “continue,” the negative of
terms like these or other comparable terminology, and other words
or terms of similar meaning. These include, among others,
statements about ONS-5010’s potential as the first FDA-approved
ophthalmic formulation of bevacizumab-vikg, including benefits
therefrom to patients, payors and physicians. Although Outlook
Therapeutics believes that it has a reasonable basis for the
forward-looking statements contained herein, they are based on
current expectations about future events affecting Outlook
Therapeutics and are subject to risks, uncertainties and factors
relating to its operations and business environment, all of which
are difficult to predict and many of which are beyond its control.
These risk factors include those risks associated with developing
pharmaceutical product candidates, risks of conducting clinical
trials and risks in obtaining necessary regulatory approvals, as
well as those risks detailed in Outlook Therapeutics’ filings with
the Securities and Exchange Commission, including the Annual Report
on Form 10-K for the fiscal year ended September 30, 2020, as
amended, and subsequent Quarterly Reports on Form 10-Q, which
include the uncertainty of future impacts related to the ongoing
COVID-19 pandemic. These risks may cause actual results to differ
materially from those expressed or implied by forward-looking
statements in this press release. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Outlook Therapeutics does
not undertake any obligation to update, amend or clarify these
forward-looking statements whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities law.
CONTACTS:
Media Inquiries:Harriet UllmanVice
PresidentLaVoie Health ScienceT:
617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024